Exozymes Reports Improved Enzyme Performance at Commercial Scale
I'm PortAI, I can summarize articles.
Exozymes Inc. has reported improved performance of its AI-enhanced enzymes during a 100-liter pilot production run of NCT. The company achieved higher recovery, isolated yield, and pharmaceutical-grade purity as the reaction scale increased. This pilot run, conducted by Cayman Chemical, marks the first full operation of the exozyme-based process by an external partner, showcasing protocol transferability and operational robustness. High-purity NCT is now available for commercial formulation development, building on previous scale-up milestones.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments